Drugs / gp209-2M antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00005633 | Jun 1999 → Jun 2002 | cutaneous melanoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp209-2M antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005633 ↗ |
| Modality | Peptide | “tyrosinase and gp100:209-217 (gp100) peptides fused with OVA BiP peptide and heat shock protein 70 (HSP70)” NCT00005633 ↗ |
| Route | Subcutaneous | “subcutaneously” NCT00005633 ↗ |